The global biologics industry was valued at US$ 448.8 billion in 2024 and is expected to reach US$ 1,140.2 billion by the end of 2035, expanding at a CAGR of 8.8% from 2025 to 2035. The market growth is driven by the increasing demand for targeted therapies, rising prevalence of chronic diseases, and continuous advancements in biotechnology and biopharmaceutical research. Additionally, growing investments in biologic drug development and the expanding adoption of monoclonal antibodies, vaccines, and cell-based therapies are further supporting the strong growth of the industry.

The biologics marketplace is growing on an unprecedented note due to visible demand for targeted therapies in conjunction with advancements in biotechnology. Biologics are complex drugs derived from living cells that provide a high level of specificity as well as effectiveness for chronic disease treatment.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15509

Key Findings of the Market Report

• Monoclonal Antibodies (mAbs) remain the dominant product category, capturing 56%–66% of the market share ($272B+). However, Gene-based biologics are the fastest-growing sub-segment, projected at a 12.1% CAGR.
• Oncology is the leading application, accounting for ~36% of revenue, followed closely by Immunological Disorders.
• Microbial and Mammalian Expression Systems are the primary sources, with mammalian systems holding a ~71% share due to their necessity in producing complex proteins like antibodies.
• In-house Manufacturing still accounts for the majority of production (~84%), but Outsourced CDMO services are growing rapidly as specialized requirements for CGT and ADCs increase.
• North America leads the market (~40%–45% share), while Asia-Pacific is the fastest-growing region (~11% CAGR) due to massive infrastructure expansion in South Korea and China.

Global Biologics: Growth Drivers in 2026

• Therapeutic Diversification: The "Obesity Gold Rush" has evolved into a platform business. In 2026, the focus has shifted from simple GLP-1 agonists to triple-agonist peptides and multi-modal metabolic therapies, with players like Novo Nordisk and Eli Lilly aggressively expanding their pipelines.
• Regulatory Acceleration: The FDA and EMA have introduced "plausible mechanism" pathways to fast-track highly personalized treatments, particularly in rare diseases and neuroregenerative medicine.
• The Biosimilar Surge: 2026 marks a turning point for biosimilar adoption. With interchangeable status becoming more common, biosimilars are projected to save global healthcare systems over USD 15 billion annually by 2026, specifically in the TNF-inhibitor and insulin categories.
• Smart Manufacturing: To combat high production costs, 85% of life science firms have increased investment in automation and IoT sensors. Single-use bioreactors now hold over 61% of the technology share, reducing facility build times by 3–5 years.

Key Players & Recent Developments

The competitive landscape is shifting toward specialized partnerships where "Big Pharma" offloads operational burdens to tech-native biotechs.

• Top Players: Roche (Genentech), Amgen, AbbVie, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Novo Nordisk, Sanofi, and Eli Lilly.
• Key CDMOs: Samsung Biologics, WuXi Biologics, Lonza, and Catalent.

Recent Milestones (Q1 2026)

• February 2026: Sanofi and Regeneron received FDA approval for an expanded indication of Dupixent, targeting allergic fungal rhinosinusitis.
• January 2026: Johnson & Johnson announced a major AI-research collaboration with Isomorphic Labs (Google-backed) to use generative biology for novel protein design.
• March 2026: Bayer’s Eylea 8mg received expanded approvals in the UK and Korea, defending its ophthalmology franchise against incoming biosimilars.
• Pipeline Watch: Innovative candidates like ABBV-RGX-314 (one-time gene therapy for AMD) and VLA15 (Lyme disease vaccine) are expected to hit the market later this year.

Buy this Premium Research Report:  https://www.transparencymarketresearch.com/checkout.php?rep_id=15509&ltype=S

Global Biologics: Segmentation

By Product Type

• Monoclonal Antibodies (Market Leader)
• Recombinant Proteins
• Vaccines
• Cell & Gene Therapies (Fastest Growth)
• Antisense & RNAi

By Manufacturing

• In-house (Largest Share)
• Outsourced/CDMO (High Growth; ~7.9% CAGR)

By Route of Administration

• Parenteral (IV/Subcutaneous) — (Dominant; ~70%+)
• Oral Biologics (Emerging Tech)

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com     
Email: sales@transparencymarketresearch.com